S846
Clinical - Lung
ESTRO 2026
having the largest age disparity between trial participants and the disease population ( − 9.75 years). Radiation oncology studies showed a lower disparity ( − 2.40 years), compared with targeted therapy ( − 9.3 years), chemotherapy ( − 9.0), or surgical studies ( − 8.3 years) (1). Systematic reviews identify restrictive eligibility criteria and clinician concerns regarding treatment toxicity as key barriers to older adult participation (1). Contrary to patient hesitancy assumptions, an Irish study of 219 cancer patients demonstrated comparable willingness to participate between older ( ≥ 65 years) and younger (<65 years) cohorts (2). Ultra-central lung tumours, unsuitable for surgery, present particular challenges for safe stereotactic ablative radiotherapy (SABR) due to proximity to major airways and mediastinal structures. The SOURCE study is a multicentre, investigator- initiated phase II study, co-developed by Cancer Trials Ireland (sponsor) evaluating the safety of dose-painted 8 × 7.5 Gy SABR in medically inoperable early-stage ultra-central non-small cell lung cancer (NSCLC) or pulmonary oligometastases. To enhance generalisability and accrual, eligibility criteria has been kept deliberately inclusive: no upper age limit, ECOG performance status 0–2, and no comorbidity-based exclusions once the multidisciplinary team deems
SABR appropriate. Material/Methods:
Baseline age and performance score demographics of patients recruited to date on the SOURCE study are summarised using descriptive statistics and compared with similar ultra-central lung SABR studies. Results: The age profile of the 54 patients recruited to the SOURCE study to date, is concordant with similar ultracentral lung SABR studies and higher than the median age of lung cancer diagnosis in Ireland (Table 1 and Fig 1).
Digital Poster 4574
Older Adults and Real-World Representation in SABR Lung Cancer Studies: Insights to date from the CTRIAL-IE 18-33 SOURCE Study. Roisin O Maolalai 1,2 , Pierre Thirion 1 , Gerry Hanna 1,3 , David Fitzpatrick 1 , Lorna Keenan 1 , Rebecca O'Donovan 1,2 , Vitor Oliveira 1 , Jessica Flood 1 , Edel Sexton 1 , Joanne O Connell 1 , Valerie Owens 1 , Vijayashree Hegde 1 , Neerej Satish 1 , Sinead Brennan 1,4 , Serena O'Keeffe 1 , Aoife Shannon 5 , Marc Nolan 5 , Vicky Donachie 5 , Bahareh Khosravi 1 , Glenn Webb 5 , John Armstrong 1,5 1 Radiation Oncology, St. Luke's Radiation Oncology Network, Dublin, Ireland. 2 Radiation Therapy, Irish Research Radiation Oncology Group, Dublin, Ireland. 3 Radiation Oncology, Trinity College Dublin, Dublin, Ireland. 4 Radiation Oncology, St. James's Hospital, Dublin, Ireland. 5 Radiation Oncology, Cancer Trials Ireland, Dublin, Ireland Purpose/Objective: Older adults are systematically underrepresented in lung cancer clinical trials (1). This under-representation poses both ethical and scientific challenges and limits the generalisability of clinical trial results to the real- world setting. The median age for diagnosis of lung cancer ranges from 61 to 73 globally. A review of 7,747 clinicaltrials.gov entries identified lung cancer as
ECOG performance status ranges from 0 to 2. Just over a quarter of patients on SOURCE had ECOG 2 at baseline, comparable to Lungtech and higher than
Made with FlippingBook - Share PDF online